No black box warning on record for Nilutamide

As of the latest FDA labeling reviewed, Nilutamide (NILUTAMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nilutamide medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Interstitial Pneumonitis Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-mark

No black box warning on record for Nilutamide

Other warnings & precautions

WARNINGS Interstitial Pneumonitis Interstitial pneumonitis has been reported in 2% of patients in controlled clinical trials in patients exposed to nilutamide. A small study in Japanese subjects showed that 8 of 47 patients (17%) developed interstitial pneumonitis. Reports of interstitial changes including pulmonary fibrosis that led to hospitalization and death have been reported rarely post-mark

Nilutamide Black Box Warning

No black box warning on record for Nilutamide

Other warnings & precautions

Nilutamide Black Box Warning

No black box warning on record for Nilutamide

Other warnings & precautions